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New generation adenoviral vectors improve gene transfer by outward from the vertices (Fig. 1) [11]. During the assem-
car-independent cell entry. Adenoviral (Ad) vectors possess bly phase of viral replication, fiber monomers trimerize
many attributes that have lead to their use as gene delivery in the cytoplasm and then bind to a viral penton base
agents in human clinical trials. However, gene transfer effi- protein that is subsequently incorporated into the viral
ciency has generally been less than that needed for meaningful
capsid. At the distal tip of each fiber monomer is a glob-clinical responses. The restricted tropism of the virus for its
ular region referred to as the knob domain. It is this knobnative receptor, the coxsackie and adenoviral receptor (CAR),
region that binds to the cellular Ad receptor, initiallyis emerging as a key limitation to the use of these agents.
By developing strategies to achieve Ad infection via alternate anchoring the virus to the cells. This receptor, the cox-
receptor pathways, enhanced and more specific gene delivery sackie/adenoviral receptor (CAR), binds the majority
can be achieved. This new generation of tropism-modified of human serotype Ads and group B coxsackie viruses
agents holds promise for the improved clinical utility of Ad [12–14]. Following attachment, viral entry requires a sec-
vectors for gene therapy. ond step, involving an interaction between Arg-Gly-Asp
(RGD) motifs in the penton base and cell surface integ-
rins (chieflyv3 orv5), which then leads to endocytosis
of the virion [15]. In the endosome, the virus undergoesAdenoviral (Ad) vectors have been used for a large
a stepwise disassembly and endosomal lysis occurs (anumber of gene therapy clinical trials, chiefly because
process mediated by the penton base and low endosomalof their high in vivo gene delivery capabilities in compari-
pH), followed by transport of the viral DNA to the cellson to other vectors [1]. Nevertheless, gene transfer effi-
nucleus [11]. This endosomolysis step is critical for effi-ciencies have been less than ideal and have compromised
cient gene delivery, and the ability of Ad to effect endo-efforts to achieve meaningful clinical responses. For ex-
somal escape is one of the key factors in its efficiencyample, in human trials for cystic fibrosis, resistance of
as a vector [16].
the target airway epithelial cells to Ad vector infection
From the foregoing, it can be seen that a relative de-
was observed [2–5]. Furthermore, several cancer gene ficiency or inaccessibility of either CAR or cellular integ-
therapy approaches based on in vivo gene delivery have rins could potentially limit the capacity of the Ad vector
also achieved suboptimal levels of gene transfer [6–9]. to accomplish efficient gene delivery. Indeed, recent stud-
Gene transfer to vascular tissues is also relatively ineffi- ies of the airway epithelium have noted a virtual absence
cient [10]. These findings indicate that the current gener- of CAR on the accessible apical surface of these cells
ation Ad vectors may not be adequate to achieve mean- [17]. This observation clearly contributes to the unfavor-
ingful clinical outcomes in many of the proposed, and able outcomes noted in the cystic fibrosis clinical trials.
endeavored, clinical gene therapy trials. In addition, a relative deficiency of CAR has been noted
An understanding of the basic biology of Ad infection in the context of a variety of other Ad-resistant targets
helps to explain the suboptimal clinical results and also [18–22]. Analysis of CAR levels in primary ovarian can-
cer cells from malignant ascites has shown that thesesuggests rational strategies for improvement. The adeno-
cells are variably low in CAR expression and that thisvirus is an icosahedral particle with 12 fibers projecting
correlates to poor transducibility with Ad vectors [23].
Currently, there is little direct information about CAR
expression in other primary tumors, but CAR deficiencyKey words: gene transfer, adenoviral infection, coxsackie virus, knob
domain. has been noted in several established and primary cell
lines, including melanoma, pancreas, lung, and glioma 2002 by the International Society of Nephrology
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Fig. 1. The pathway of adenoviral infection. Primary
binding is mediated by the interaction of the knob do-
main of the Ad fiber with the cellular receptor, CAR.
This is followed by an interaction between RGD motifs
in the penton base with cellular integrins, which mediates
internalization of the virion into an endosome. Endoso-
mal disruption occurs via mechanisms involving the pen-
ton base and the low endosomal pH. The partially disas-
sembled virion particle is then transported to the nuclear
membrane for release of viral DNA into the nucleus.
[18, 24, 25]. In these analyses, a direct correlation be- targeting adapters, which simultaneously bind to Ad and
to a cellular receptor (Fig. 2) [26]. These adapters typi-tween CAR expression and infectability with Ad vectors
has also been noted. In other studies using primary mate- cally have been designed to have specific recognition for
the knob domain of the Ad fiber protein. The rationalityrial, CAR deficiency has been inferred by Ad resistance
to infection, which has successfully been overcome by of this approach was that one could simultaneously ab-
late native tropism and impart new tropism, therebyretargeting strategies as discussed later in this article
(for example, to head and neck tumor) [20]. Although potentially improving both efficiency and specificity of
Ad infection. Successful retargeting of Ad has beenintegrin expression also plays a role in the cell-entry
pathway of Ad, for the most part, CAR levels have achieved using a variety of chemical conjugates between
an anti-knob Fab and natural ligands specific for cell sur-emerged as the dominant limiting factor as integrins are
more widely expressed. Importantly, the key issue of face receptors [folate [26], fibroblast growth factor (FGF)
[27–30], tetanus toxin fragment [31]), as well as antire-CAR expression has not received significant attention
in the design of Ad vector-based gene therapy trials to ceptor antibodies (including anti-epidermal growth fac-
tor (anti-EGF-R) [18], anti-EpCAM [32], anti-TAG-72date. Thus, for the achievement of efficient gene delivery
to cells in clinically relevant settings, the exploitation of [23], and anti-CD40 [33]].
Employment of this retargeting approach has estab-CAR-independent cell entry pathways may provide a
generalized means to circumvent CAR deficiency, which lished several key concepts for achieving improvements
in Ad vector efficiency. First, it is now well establishedmay be broadly relevant to many target cells, including
tumors and normal parenchyma. At the very least, it is that Ad can achieve effective gene delivery via CAR-
independent cellular entry pathways. Thus, the targetedclear that some understanding of the level of CAR ex-
pression on the particular cells one wishes to treat is virion’s interaction with CAR did not appear to be cru-
cial to its effective cellular entry capacity and the criticalneeded before embarking on protocols using native-tro-
pism vectors. For the treatment of tumors, this suggests subsequent steps of endosomal escape. Second, CAR-
independent cell infection allowed enhanced levels ofthe need to include CAR analysis of primary material
from individual patients in the pretreatment evaluation, gene transfer improving the susceptibility of many target
cells in vitro and, at least locoregionally, in vivo [34].in much the same way as other tumor markers have been
used to help guide rational therapeutic decisions. Third, the new target receptor did not necessarily need
intrinsic internalization capabilities, suggesting the na-In an effort to overcome the tropism limitations of
Ad, strategies have been devised to redirect the vector tive penton-base integrin interaction may still provide
this function, thereby broadening the range of potentialto alternative cellular receptors. If one could target to
receptors that are expressed on the cell surface at higher targets one could consider. Fourth, for those cells that
lack both CAR and integrins (for example, T lympho-levels than CAR, improved efficiency could be achieved.
Several strategies to achieve such CAR-independent gene cytes), retargeting could achieve both of these functions
(in this case by targeting to CD3 [35]). Fifth, enhancedtransfer have been devised. In one approach, this goal
has been addressed by the development of bispecific infectivity was shown to translate to improved therapeu-
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Fig. 2. Redirection of adenoviral infection mediated by
conjugate of FGF2 with the Fab fragment of an antiknob-
neutralizing mAb achieves enhanced gene delivery. (A)
Retargeting schema. (B) 3H-labeled Ad vector alone or
after incubation with Fab or Fab-FGF2 was bound to
human umbilical vein endothelial cells at 4C for one
hour. Following washing, cell bound radioactivity (CPM)
was measured in a scintillation counter. (C ) The optimal
neutralizing dose of Fab or Fab-FGF2 was incubated
with 108 particles of an Ad vector carrying the luciferase
reporter gene (AdCMVLuc). After 30 minutes, the com-
plexes were added in triplicate to 24-well plates con-
taining vein endothelial cells. After incubation for 24
hours at 37C, cells were lysed, and extracts were assayed
for luciferase activity. Specificity of FGF2 retargeting
was confirmed by blocking with heparin, excess FGF, or
anti-FGF antiserum. Free FGF2 alone had no stimula-
tory effect on Ad-mediated luciferase expression (adapted
from Reynolds et al [29]).
tic outcome [36]. Using a locoregional murine model of context, this study has encouraging implications for the
continued development of targeted Ad vectors, althoughovarian carcinoma, two key principles were established:
improved outcome at equivalent Ad dose with targeting the issue of non-receptor–mediated sequestration of vec-
tor by the reticulo–endothelial system still needs to beor similar outcome at a lower dose of Ad particles when
targeting was used, the latter result thus suggesting a addressed. Furthermore, this study and those using an
FGF conjugate are beginning to address one of the keymechanism to reduce the well-recognized dose-dependent
toxicity associated with Ad vectors. Subsequent studies concerns of the conjugate approach, that being whether
the bond between conjugate and virus is sufficiently sta-also indicated that retargeting could reduce ectopic he-
patic transgene expression and thereby mitigate against ble to enable systemic application. In contrast to some
earlier predictions, the results so far in this regard arethe hepatic toxicity associated with suicide gene therapy
for cancer [30]. Sixth, the targeting moiety itself may act encouraging.
The technical achievement of Ad retargeting via pro-to improve the overall biological activity of the gene
delivery strategy, as with the use of anti-CD40 targeting tein complexes has now been approached by a variety
of methods. In addition to attachment to the Ad knob,to enhance dendritic cell activation in response to an
Ad-delivered DNA vaccine [37]. bispecific antibodies have also been derived that bind at
the penton base and reduce native tropism for CAR byRecently, the development of antibody targeting con-
jugates has been taken a step further with the demonstra- steric hindrance [39, 40] or attach to Ad hexon protein
[41]. Recombinant antibody strategies have also beention that this approach also has a degree of fidelity in
the stringent context of in vivo systemic vascular admin- used, for example, a fusion protein consisting of an anti-
knob single chain antibody (scFv), and EGF has beenistration [38]. In this study, a conjugate that targets to
angiotensin-converting enzyme was used to target Ad constructed [42]. Dmitriev et al recently developed an
alternate approach, using a complex consisting of theselectively to pulmonary vascular endothelial cells upon
tail vein injection into rats. This approach achieved a ectodomain of CAR in fusion with EGF [43]. This recom-
binant fusion protein effectively retargeted the vector viagreater than 20-fold enhancement of transgene expres-
sion in the target cells, while simultaneously reducing non-CAR pathways to EGF-positive cells. Recombinant
strategies such as this may indeed offer a more efficientinfection of nontarget organs, especially the liver, the
predominant site of Ad vector sequestration. Thus, the and reproducible means to produce targeting conjugates
than chemical linkage approaches.twin goals of enhancement and selectivity were achieved
and may ultimately be applied to gene therapy ap- Advances are also being made in the engineering of
ligands per se. In addition to natural ligands (and frag-proaches for pulmonary vascular disease. In the broader
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ments) and antibodies (including Fab fragments and
scFvs derived thereof), phage-panning approaches have
been used to identify novel peptide sequences with tar-
geting specificity [44]. These peptides have then been
successfully incorporated into targeting conjugates and
have achieved targeting fidelity in vitro [45–47]. This
combination of target definition with targeted delivery
still further broadens the prospects for the development
of improved vectors.
The use of conjugate-based targeting approaches has
the advantage that a multitude of established targeting
moieties can readily be incorporated into the system.
Furthermore, many Ad vectors containing different ex-
pression cassettes can quickly be combined with any
targeting moiety, thereby offering a high degree of flexi-
bility. However, this “two-component” approach adds a Fig. 3. Genetic modification of the HI loop of the fiber knob domain.
The knob trimer, viewed along the three-fold symmetry axis (picturedegree of complexity to the system, which may not be
courtesy R. Gerard, adapted from Xia et al [51]). The position of theideal for ultimate clinical application. Thus, vector trop- HI loops, into which the targeting RGD motif was inserted, is shown.
ism modification has also be achieved by genetic meth- The accessibility of this region for binding to cellular targets is seen.
ods, in an effort to produce a single targeted vector
particle [48]. As Ad capsid proteins are the basis of viral
binding and internalization, these proteins are the focus
where the HI loop extends outward and appears accessi-
of this approach. Wickham et al have altered the Ad ble for targeting purposes (Fig. 3).
fiber gene, thereby adding cell-binding peptides to the Krasnykh et al first determined that modifications to
carboxy terminus of the translated protein [49]. Evalua- the HI loop were compatible with viable virus generation
tion of viruses possessing these fibers showed that en- and that inserted sequences were accessible for binding,
hanced infection and gene transfer could be achieved by using a FLAG peptide motif as a convenient marker
using a limited range of targeting ligands. Using a vector [52]. Then, based on the loop nature of the region being
in which an integrin-binding RGD motif had been added modified and on the recent identification of constrained
to the C terminus of the fiber, enhanced, CAR-indepen- cyclic peptides that have targeting potential, Dmitriev
dent gene delivery was achieved to human vascular endo- et al inserted an RGD-4C sequence into the HI loop
thelial cells in culture and to the cortical vasculature of [19]. This sequence had been shown to have a degree of
specificity for tumor vasculature in studies using a novelthe rat kidney by ex vivo infusion of vector into the renal
in vivo phage-panning technique [53]. Studies of recom-artery. In a separate study, a vector having a C-terminal
binant Ad fiber protein containing the mutation clearlypolylysine addition to enhance binding to heparin sul-
confirmed that this motif could bind to integrins whenfates achieved improved gene delivery to the vascular
placed at this site. The resulting Ad vector had markedlysmooth muscle cells of the porcine iliac artery in a bal-
enhanced ability to infect CAR-negative cells. Most im-loon injury model [50]. Thus, these studies established
pressively, when this vector was evaluated using primarythe feasibility of enhanced gene delivery through genetic
tumor tissue, significantly enhanced infectivity was againfiber modification.
noted compared with the unmodified vector, in some casesAlthough carboxy-terminus modifications of fiber were
by up to three orders of magnitude [54]. In the con-able to establish an important principle, this location may
text of a conditionally replicative Ad designed to achieve
be suboptimal for ligand addition. The major problem in tumor cell killing by viral replication and oncolysis, we
this regard is that the upper limit of size for incorporated have recently shown that infectivity enhancement via the
sequences is quite small before the structural integrity RGD-HI loop modification led to improved therapeutic
of the knob trimer is disrupted. Furthermore, crystal outcome in a murine model [55].
structure analysis of the knob domain indicates that the The addition of an RGD motif into the HI loop clearly
C terminal is not in an ideally accessible location. More altered the infection dynamics of the virus. Furthermore,
recently, the HI loop of the knob has become a popular the in vivo systemic administration of vector also resulted
site for the insertion of targeting ligands. This choice of in some modification of the biodistribution of transgene
this location was pioneered by Krasnykh et al and is expression [56]. Although liver expression still predomi-
nated (consistent with the fact that this vector still recog-based on the crystal structure of the knob domain [51]
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nizes CAR), relative increases in other organs, especially ble using the peptide sequences compatible with C-termi-
nal or HI-loop insertion is yet to be determined. Thethe kidney, implied that the RGD motif was available
for target cell interaction in this stringent delivery con- specificity of promising bicyclic ligands defined by in
vivo phage panning is exquisitely dependent on correcttext and thus that the HI loop might prove a useful site
for the introduction of more specific targeting moieties. formation of the cyclic disulfide bonds within the peptide,
and whether this can be achieved in the HI loop is uncer-Subsequent studies have established that peptides of
up to 63 amino acids in size could be incorporated at tain. In fact, thus far, few successful peptide insertions
in the HI loop have been reported. Alternate strategiesthe HI loop without deleterious effects with respect to
the quaternary structure of the fiber or viral infection to replace entirely the Ad knob domain with novel pro-
teins that can achieve the correct trimerization of fiberdynamics (unpublished data).
Improving Ad infectivity via the modification of capsid as well as posses specific targeting attributes are now
also being developed [61–63]. Such approaches may haveproteins besides knob has also been evaluated. In this
regard, Vigne et al introduced an RGD motif into the much greater flexibility with respect to the potential
choice of targeting ligand.hexon protein [57]. As there are 720 hexons compared
with 36 knob domains on the virus, the greater number In addition to achieving targeted gene expression via
tropism modification, expression can be controlled at theof targeting ligands with the hexon approach might offer
some advantage. However, as these moieties are located level of transcription, through the use of cell-specific pro-
moters. This strategy can help reduce the level of unde-close to the virion surface, their interaction with recep-
tors might be compromised by steric hindrance from the sirable transgene expression seen in organs such as the
liver and spleen, which have a high propensity for non-fibers. Nevertheless, a significant enhancement of trans-
duction to CAR-negative cells was achieved in vitro us- specific vector uptake. However, the use of putative cell-
specific promoters in Ad vectors can be difficult becauseing this approach. Shortening of fiber length to improve
hexon accessibility could potentially further improve these there is often a tendency for the specificity of the pro-
moter to be undermined when placed in the Ad genomeresults. A rigorous, systematic comparison of the different
strategies of fiber and hexon modification with respect to because of ill-defined cis- or trans-acting factors. Never-
theless, several promoters that do retain specificity inthe enhancements achieved has not been reported.
The foregoing genetic modification strategies have this setting are emerging [64–66], and strategies to place
insulator sequences before or either side of the expres-achieved enhanced infectivity but have not improved
specificity, chiefly because all of the modified vectors sion cassette also help [67]. We recently investigated whe-
ther a combination of appropriate transductional andretained recognition for CAR. Thus, although they rep-
resent a significant advance for many disease applications transcriptional targeting approaches would significantly
improve the transgene expression profile in vivo comparedwhere delivery can be limited locoregionally, greater
specificity is required for broader application. Recently, with either strategy used alone [68]. Thus, we combined
the conjugate-based pulmonary vascular targeting ap-the genetic manipulation of the Ad5 knob to ablate its
natural recognition for CAR and yet still retain the struc- proach to angiotensin-converting enzyme, with the use
of an endothelial-specific promoter, the promoter for thetural integrity of the virus has been achieved [58]. Fur-
thermore, a mutation of the penton base to ablate the vascular endothelial growth factor receptor type 1 (f/t-1)
[64]. The combination resulted in a remarkable syner-natural recognition for integrins has also been accom-
plished. Nevertheless, the ablation of CAR recognition gistic improvement in the specificity of transgene expres-
sion for the pulmonary target site (over 300,000-foldalone does not significantly reduce vector localization to
the liver after systemic administration, nor does it reduce improvement compared with untargeted vector) (Fig. 4).
These results represent the first successful combined tar-hepatocyte transduction [59, 60]. Preliminary studies us-
ing vectors in which the penton RGD has also been geting approach. As technology improves in both target
definition and promoter development, many other ratio-ablated still show that the vast majority of vector local-
izes to the liver (unpublished observations). However, nal combinations for other tissues and disease could be
envisaged.these studies have been performed using vectors that do
not have a specific alternate ligand. Interestingly, there Aside from issues of receptor-specific transduction
and of CAR, a major issue concerning the use of Adis now some in vitro evidence that Ad vectors can also
achieve primary attachment to cells by binding to he- vectors for systemic administration is sequestration of
the vector by Kupffer cells. It has been shown that atparan sulfates, although this mechanism is yet to be fully
characterized (Note added in proof). The relevance of low vector doses, 90% or more of the injected dose is
taken up by the Kupffer cells by phagocytosis and de-this mechanism in vivo has not yet been reported, how-
ever. The superimposition of a specific targeting moiety graded, without leading to transgene expression [69].
This clearly has implications for the issue of Ad-relatedonto a background of a native tropism-ablated vector is
eagerly awaited. Whether such a construct will be possi- direct inflammatory responses. Vector-associated toxic-
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Fig. 4. Combined transductional and tran-
scriptional targeting improves the specificity
of transgene expression in vivo. Stepwise im-
provement in transgene expression in pulmo-
nary endothelium is shown. Rats were injected
via the tail vein with vectors carrying the lucif-
erase reporter gene. Then organs were har-
vested, and luciferase activity was determined
three days later. (A) Untargeted vector, Ad-
CMVLuc, showing dominant transgene expres-
sion in liver and spleen. (B) Addition of Fab-
9B9 for targeting to angiotensin-converting
enzyme leads to enhanced pulmonary gene
expression and reduction in liver expression
(note log scale). (C) AdfltLuc, containing an
endothelial specific promoter results in dra-
matic reduction in expression in all organs.
(D) AdfltLuc  Fab-9B9 restores transgene
expression levels in lungs but still further re-
duces expression in nontarget liver and spleen,
thereby dramatically improving selectivity ra-
tio (adapted from Reynolds et al [68]).
ity observed in human clinical trials is closely linked to NOTE ADDED IN PROOF
Deghecci MG, Melotti P, Bonnizzato A, et al: Heparin sulfatethe magnitude of particle dose. If Kupffer cell uptake
glycosamino-glycans are receptors sufficient to mediate the initial bind-could be avoided, a much lower dose of vector could be
ing of adenovirus types 2 and 5. J Virol 75:8772–8780, 2001
administered. Currently, several groups are working on
strategies to coat the virus with polymers such as polyeth-
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